Not Yet RecruitingPhase 2

Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO

Czechia200 participantsStarted 2027-01

Plain-language summary

The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ECMO support with anticoagulation using argatroban/enoxaparin * Age ≥ 18 years * Obtaining informed consent in accordance with the procedure specified in the protocol Exclusion Criteria: * Enrolment in the lung transplant program at Motol University Hospital * Known hypersensitivity to the components of the evaluated products * Allergic reaction to the active ingredients of the evaluated products * Pregnancy and breastfeeding

What they're measuring

Safety of bleeding complications

Timeframe: During ECMO, up to 4 weeks

Safety of thrombotic complications

Timeframe: During ECMO, up to 4 weeks

Trial details

NCT IDNCT07499037

SponsorUniversity Hospital Ostrava

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-09

Contact for this trial

Jiří Hynčica

+42059737 jiri.hyncica@fno.cz

View on ClinicalTrials.gov More Pneumonia trials